Scribe Therapeutics priced a $129 million IPO on Thursday — the first gene editing company to go public in over two years — and shares begin trading Friday on the Nasdaq under "SCTX." Co-founded by CRISPR pioneer Jennifer Doudna, Scribe kicks off what analysts expect to be a busy second-half biotech IPO slate. The real story is the pattern: Zetwerk, a B2B manufacturing unicorn, raised a ₹500 Cr pre-IPO round at a $4 billion valuation days after SEBI cleared...